Although ErbB3, a member of the epidermal growth factor receptor family, has been implicated in mammary tumorigenesis, investigation of its role in lung tumorigenesis has been limited. We found that ErbB3 was present at high levels in five of seven human lung adenocarcinoma cell lines examined, along with its ligands, heregulins a and b, whereas ErbB3 was absent from HPL1D, a nontransformed cell line from human pulmonary peripheral epithelium. Interactions and effects of ErbB3 were studied in detail in adenocarcinoma lines H441 and H1373. Complexes containing phosphorylated ErbB2, phosphorylated ErbB3 and the p85 regulatory subunit of phosphoinositidyl 3-kinase were detected by co-immunoprecipitation experiments and were present constitutively even in the absence of serum-stimulated cell division. Serum treatment increased the pErbB3/p85 complexes and also stimulated phosphorylation of Akt and GSK3b, increase in cyclin D1 and cell cycle progression, and these events were blocked by the Akt activation inhibitor LY294002. An ErbB3-specific antisense oligonucleotide reduced amounts of ErbB3 protein and p85 complex in both cell lines, and significantly suppressed cell proliferation. These results together suggest involvem`ent of ErbB3 in growth of lung adenocarcinomas, through activation of phosphoinositidyl 3 kinase and Akt, inactivation of GSK3b and stabilization of cyclin D1 for cell cycle maintenance. It could be a useful therapeutic target.
Introduction
The four members of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, ErbB1(EGFR), ErbB2, ErbB3 and ErbB4, and the dozen or more ligands that activate them, mediate proliferation, differentiation, migration, cell survival or apoptosis through a complex network of signaling, in a cell-specific manner (1, 2) . These receptors contain an extracellular ligand-binding domain, a single hydrophobic transmembrane domain and an intrinsic tyrosine kinase cytoplasmic domain (3) . Of these, ErbB3 lacks intrinsic kinase activity (4) . Different isoforms of Neu differentiation factor/heregulin (also known as neuregulin) bind to ErbB3 (5) . No direct ligand for ErbB2 has yet been discovered (6) . The mature soluble forms of heregulins (HRGs) act as autocrine and paracrine factors while the membrane-associated precursors act through a juxtacrine pathway (7) .
Each ErbB receptor has unique properties with regard to ligand affinity, rate of down-regulation and tyrosine kinase activity (8) . Specific ligands can elicit distinct signals downstream of a given ErbB receptor, as a function of the specific profile of tyrosine phosphorylation of the receptor (9) . Upon ligand binding the ErbB receptors homo-and heterodimerize in various combinations. The transphosphorylation between the receptor subunits in a dimeric complex diversifies the biological response, by recruiting various downstream signaling molecules (10) . The type and amplitude of signaling depend upon the co-expression of these receptors and the ligand availability in the cellular context. This complexity dictates that growth factor/ErbB pathways be examined in detail for every cell and cancer type of interest. In the human fetus, EGFR, ErbB2 and ErbB3 were detected in the epithelium of developing lung, and NRG-1 treatment of fetal lung explants resulted in increased proliferation and reduced differentiation (11, 12) . In normal adult human lung, EGFR, ErbB2, ErbB3, EGF, TGFa, amphiregulin and heparin-binding EGF were detected by immunohistochemistry in the bronchial epithelium (13, 14) . Cultured human bronchial epithelial cells expressed TGFa, amphiregulin, betacellulin, heparin-binding EGF and heregulin (15, 16) .
Less certain is the presence of ErbB receptors and ligands in normal adult alveolar/bronchiolar cells, the precursors of adenocarcinoma. Several immunohistochemical and RNA analyses in human lung noted the absence of EGF from alveolar cells (13, 17, 18) . Immunoelectron microscopy confirmed the presence of EGFR for normal human adult type II pneumocytes, with staining limited to lateral cell membranes at attachments to adjacent epithelial cells (13) . Immunohistochemical studies reported moderate staining for ErbB3 in adult alveolar cells (19, 20) , but absence of ErbB2 (11, 19) .
There is much evidence that ErbB receptors and ligands contribute to lung tumorigenesis. The EGFR may have high levels of expression in non-small cell lung carcinoma (NSCLC) (21) . This over-expression has correlated with poor prognosis in some studies (21±23) but not others (24±26). Over-expression of EGFR was reported at an early stage of basal cell hyperplasia, and persisted through squamous metaplasia, dysplasia and carcinoma in situ (27) . Iressa, a small molecular weight inhibitor of EGFR, had activity against nonsmall cell cancers in clinical trials (28, 29) .
ErbB2 is over-expressed in~30% of lung tumors and in up to 100% of lung adenocarcinomas, with associated poor prognosis, especially for lung adenocarcinoma (30±32). Coover-expression of ErbB2 and EGFR also correlated with poor prognosis (26) . However, over-expression of ErbB2 alone did not transform bronchial epithelial cells (33) . Clinical trials of an anti-ErbB2 reagent, herceptin, gave negative results for lung cancer (34) .
Very limited data are available for ErbB3 in lung cancer. As measured by immunohistochemistry, ErbB3 was highly expressed in some lung adenocarcinomas (35) and associated with poor prognosis (20) . Co-expression of ErbB3 with other members of the ErbB family has not been well studied. One immunohistochemical study indicated that ErbB3 coexpression with other ErbB family members was a marker for lung tumor recurrence (36) .
New evidence for the importance of ErbB3 in lung tumorigenesis has come from ErbB3 transgenic mice treated with the carcinogen methylnitrosourea: these developed a high incidence of lung tumors, with reduced latency (37) . Furthermore, doubly transgenic mice over-expressing both human ErbB3 and rat ErbB2 had a shorter lung tumor latency compared with the singly transgenic ErbB3 mice (37) .
Most investigations of ErbB3-related signaling have been focused on breast and ovarian cancer cells. In these cells ErbB2/ErbB3 heterodimers activate various signaling pathways (38±40). Growth inhibition of ovarian cancer cells with an ErbB3 receptor antibody (41) and of breast cancer cells with dominant-negative ErbB3 (42) have been recently reported. No therapeutic antibodies against ErbB3 are currently available.
In this study, we examined the expression and activation state of ErbB3 in human lung adenocarcinoma cell lines and found that ErbB3 is constitutively activated at a high level in several lung adenocarcinoma cell lines, which also express ErbB2. We demonstrate the presence in these cells of complexes of ErbB3, ErbB2 and the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K). Serum treatment augmented amount of ErbB3/p85 complex, activated the PI3K/ Akt pathway and promoted cell proliferation. We also provide evidence for ErbB3 mediating growth in these lung adenocarcinoma cells by inhibiting their proliferation with antisense ErbB3 oligonucleotides.
Materials and methods

Cell lines and culture conditions
Human lung adenocarcinoma cell lines were obtained from the American Type Culture collection and were cultured in RPMI 1640 medium supplemented with 2 mM glutamine, penicillin/streptomycin and 10% fetal calf serum. HPL1D immortalized non-transformed cells from human peripheral lung epithelium show characteristics of both type II alveolar and bronchiolar Clara cells (43) . HPL1D cells were maintained in Ham's F-12 medium buffered with 15 mM HEPES (pH 7.3; BioFluids, Rockville, MD) and supplemented with 5 mg/ml bovine insulin (Sigma Chemical Co., St Louis, MO), 10 À7 M hydrocortisone (Sigma), 2 Â 10 À10 M triiodine thryonine (Sigma), 100 IU/ml penicillin (BioFluids) and 3% fetal calf serum (Gemini BioProducts, Calabasas, CA).
For serum starvation experiments, 70% confluent cultures were maintained in media with 0.1% serum for 48 h, and rinsed with fresh 0.1% serumcontaining media 2 h prior to the experiment. Serum starvation for 48 h greatly suppresses growth of the cell lines (see Figure 6 ). LY294002 (50 mM) (Sigma) was added 30 min before the addition of 10% serum.
Immunoprecipitations and immunoblots
Cultured cells for immunoprecipitations or immunoblots were rinsed with cold phosphate-buffered saline (PBS, 17 mM KH 2 PO 4 , 50 mM Na 2 HPO 4 and 150 mM NaCl) and scraped in lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mg/ ml leupeptin (Cell Signaling Technology, Beverly, MA) and supplemented with 1 mM phenylmethylsulfonyl fluoride (Sigma Chemical Co.) just before use. For immunoprecipitation, cells were prepared in lysis buffer as described above and 1 mg of protein was immunoprecipitated with antibodies overnight at 4 C. Protein A or G agarose (Roche Molecular Biochemicals, Indianapolis, IN) was added and incubation continued for 2 h at 4 C. The immunoprecipitates were washed three times in lysis buffer prior to electrophoresis and immunoblotting.
For immunoblotting, the cell lysates were loaded at the protein concentration indicated in the figure legends on Tris-Glycine gels (Invitrogen, Carlsbad, CA), 6% gels for growth factor receptors, and 12% gels for Akt, GSK3b and cyclin D1, and electrophoresed at 100 V. After transfer to Hybond nitrocellulose membranes (Amersham, Buckinghamshire, UK) at 22 V at room temperature, the blots were blocked either in 3% bovine serum albumin or 3±5% dried milk for 2 h at room temperature and probed overnight with antibodies. Antibodies to EGFR, ErbB2, ErbB3, heregulin a, heregulin b and total GSK3b kinase were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to ErbB3, phospho-specific ErbB2, phosphotyrosine (clone 4G10), PI3K p85 (mouse monoclonal, clone UB93-3), PI3K p85 polyclonal and cyclin D1, were from Upstate Biotechnology (Lake Placid, NY). Antibodies to Akt, phospho-Akt and phospho-GSK3b were from Cell Signaling Technology. Detection of the bound antibody was by ECL (Amersham). Antibody dilutions for immunoblotting were 1:1000, except for 1:100 dilution for anti-p85. The blots were stripped in buffer containing 100 mM 2-mercaptoethanol, 2% sodium dodecyl sulfate and 65 mM Tris, pH 6.8, for 30 min at 60 C and washed for 1 h with PBS plus 0.1% Tween 20 before reprobing with another antibody.
Fluorescence-activated cell sorting (FACS) Cells were treated as described in the figure legends, trypsinized, washed twice with ice-cold PBS, resuspended in PBS and fixed by adding absolute ethanol to a final concentration of 70% and left at À20
C. The day before the FACS analysis cells were washed with PBS and resuspended in PBS and the cell nuclei were stained in the dark with 100 mg/ml propidium iodide (Sigma) containing 125 U/ml RNase and left overnight at 4 C. The next morning, a total of 10 000 stained nuclei were analysed in a Coulter XL flow cytometer, using system II version 3.0 software.
Antisense oligonucleotides
The phosphorothioate backbone oligonucleotides targeting the 5 H region of the ErbB3 mRNA molecule were synthesized by Qiagen (Valencia, CA). The sequences for ErbB3 antisense (AS), scrambled control (SC) and sense control (SE) oligonucleotides were: AS: 5 H CCTCATGACTCCGCA; SC: 5 H CCACT-TACGGCTCAC and SE: 5 H TGCGGAGTCATGAGG, respectively. A BLAST search of the NCBI database revealed no match of the oligonucleotides to other human genes. Oligonucleotides were delivered to cells as a Lipofectin complex. Diluted oligonucleotides were mixed with 10 mg/ml Lipofectin (Invitrogen) in serum and antibiotics free media (Opti-MEM media from Invitrogen). Cells were exposed to lipofectin:oligo complex for 4 h and then the transfection media was replaced with media containing 10% serum and the cells incubated for an additional 24 h. Thirty hours after transfection, cells were analysed for ErbB3 protein expression by western blotting.
Determination of cell numbers
MTT (3-[4,5-dimethylthiazol 2-yl]-2,5-diphenyltetrazolium bromide) assay was used to assess cell numbers, using a kit from Roche Applied Sciences. 5 Â 10 3 cells were plated in 96-well plates and incubated for 24 or 48 h. Following transfection with 1 mM concentration of oligonucleotides, cells were incubated for an additional 72 h and assayed for number of viable cells as per the manufacturer's instruction. Substrate cleavage was monitored at 570 nm using a Biotech microplate reader. Statistical analysis (paired t-test or nonparametric tests as appropriate) was carried out using GraphPad InStat version 3.00 for Windows 95, GraphPad Software, San Diego, CA.
Results
ErbB3 is expressed in most human lung adenocarcinoma cells but not in the non-transformed human lung HPL1D cell line To evaluate any altered expressions in ErbB family members or agonists that may be associated with the transformed phenotype, we compared the non-transformed human lung cell line HPL1D from the peripheral epithelium, with two malignant cell lines from human adenocarcinomas, H441 and H1373, for the expression of ErbB family members by western immunoblot analysis (Figure 1 ). High levels of EGFR and ErbB2 were seen in both transformed and non-transformed cells. Strikingly, ErbB3 was expressed only in the two malignant cell lines; it was absent from HPL1D cells.
Heregulin a (HRGa), and heregulin b (HRGb), ligands for ErbB3, were found in both transformed and non-transformed cell lines. The co-occurrence of ErbB3 and HRG isoforms in the malignant cells suggested a contribution of an HRG/ErbB3 autocrine loop to maintenance of the malignant phenotype of these cells.
To investigate the generality of the high expression of ErbB3 in human lung adenocarcinoma cells, several additional lines were tested. Of these, threeÐA549, H1395 and H1355Ðwere positive (data not shown) and twoÐH23 and H1792Ðwere negative for ErbB3 protein (see Figure 10A ).
ErbB3 and ErbB2 are constitutively active in H441 and H1373 cells
ErbB3 immunoprecipitates from serum-starved cells were subjected to immunoblot analysis using anti-phosphotyrosinespecific antibodies (Figure 2A ). The results indicated that ErbB3 is constitutively activated in these cells in the absence of serum growth factors. Reciprocal anti-phosphotyrosine immunoprecipitations blotted with ErbB3 antibody confirmed this observation ( Figure 2B ).
Western blotting with phospho-specific ErbB2 antibody indicated that ErbB2 is also constitutively phosphorylated in these cells ( Figure 2C) , with the highest levels in H441 and least in HPL1D. Immunoprecipitations with anti-ErbB2 antibody followed by immunoblotting with anti-phosphotyrosine antibody confirmed this observation ( Figure 2D ). These high levels of phosphorylated ErbB2 and ErbB3 in the absence of serum indicate that an HRG/ErbB2/ErbB3 autocrine loop may be active in these cells.
The p85 regulatory subunit of PI3K co-immunoprecipitates with ErbB3 in proliferating and serum-starved H441 and H1373 cells Since ErbB3 is highly expressed in these cells, and activated ErbB3 has high affinity for the p85 regulatory subunit of PI3K, we investigated ErbB3/p85 interaction by coimmunoprecipitation with either anti-p85 or anti-ErbB3. In both adenocarcinoma cell lines, the p85 subunit of PI3K coimmunoprecipitated with anti-ErbB3 ( Figure 3A ) and reciprocally ErbB3 co-immunoprecipitated with anti-p85 ( Figure 3B ). This confirmed that a protein complex between ErbB3 and p85 is indeed formed in these malignant cells. Even under serumstarvation conditions, both cell lines contained a complex of ErbB3 and the p85 subunit of PI3K, which was immunoprecipitated by either anti-ErbB3 ( Figure 3A ) or anti-p85 ( Figure 3B ). The ErbB3/p85 complex was especially prominent in H441 cells.
Next, we examined whether the ErbB3 present in the complex was indeed the activated ErbB3. The blot with the complex immunoprecipitated by anti-ErbB3 was probed with anti-phosphotyrosine antibody; strong bands indicated that the ErbB3 receptor in 441 and 1373 cells was tyrosine phosphorylated ( Figure 3A) . Immunoprecipitation with ErbB3 in lung adenocarcinoma anti-phosphotyrosine followed by immunoblotting with antiErbB3 confirmed this observation ( Figure 3C ). The levels of activated ErbB3 in the p85 complex appear to be higher in the serum-starved cells than in those rapidly proliferating, again suggestive of operation of a vigorous autocrine loop. (38, 39) . An association between ErbB2 and ErbB3 was detected both in quiescent and serum-stimulated H441 and H1373 cells (Figure 4 ). Immunoprecipitates obtained with anti-ErbB3 contained ErbB2 as well as p85 ( Figure 4A ). Anti-ErbB2 immunoprecipitate included ErbB3 and p85 ( Figure 4B Figure 5A ). Emerging evidence implicates the PI3K/Akt pathway as a major driver of proliferation in a number of normal and cancerous epithelial cells (44±47), including those of lung (48±50). Therefore, we examined the level of activated Akt, a downstream target of PI3K, in serumstimulated H441 and H1373 cells using a phospho-serinespecific anti-Akt antibody. Phosphorylated Akt was detected in serum-starved cells, and treatment with serum led to an~4-(H1373) to 10-fold (H441) increase in activated phosphorylated Akt in these cells ( Figure 5B ). Time course experiments indicated that the phosphorylation of Akt in H1373 cells increased within 10 min of stimulation and remained active at least up to 6 h, the longest time point tested ( Figure 5C ; 6 h time point not shown). Amounts of phosphorylated Akt were reduced by~50±80% to constitutive levels or below when the specific LY294002 inhibitor was included ( Figure 5B and C) .
ErbB2 is
The ErbB3/PI3K/Akt pathway is implicated in cell cycle progression and cell survival In order to assess the importance of PI3K pathway in the growth of these malignant lung cell lines, we studied the impact of the specific PI3K inhibitor, LY294002, on cell cycle progression by FACS analysis. Serum starvation of H441 and H1373 cells led to a 50±60% reduction in percentage S phase cells and a doubling of those in G 0 /G 1 ( Figure 6 ). Treatment of proliferating cells with the LY294002 for 24 or 48 h had a similar suppressive effect on proliferation (data not shown). This was studied further in cells serum-starved for 48 h, followed by re-stimulation with serum ( Figure 6 ). Twenty hours after re-feeding of serum-starved cells, high percentages of H441 and H1373 cells had entered S G 2 /M phases, 46% for H441 and 69% for H1373. This re-activation of the cell cycle was completely blocked by inclusion of LY294002, resulting in S G 2 /M values less than those for serum-starved H441 cells ( Figure 6A ) and similar to those for serum-starved H1373 cells ( Figure 6B ). Thus, PI3K activity is essential for serum-induced cell cycle progression in these human lung adenocarcinoma cells.
Levels of apoptosis were low (0.5±1.1%) in these cell lines, as determined by FACS analysis. No consistent increases in these percentages occurred after treatment of the cells with LY 2940002 (data not shown).
Serum treatment increases inactivating phosphorylation of glycogen synthase kinase 3b and levels of cyclin D1 in human lung adenocarcinoma cell lines Akt is known to inactivate glycogen synthase kinase 3b (GSK3b) through phosphorylation. GSK3b is a negative regulator of cyclin D1, targeting it for proteosomal degradation Figure 7A ) and the levels of pGSK3b were reduced to constitutive levels or below when LY294002 inhibitor was included ( Figure 7A ).
In these human lung carcinoma cells levels of cyclin D1 were increased within 30 min of serum stimulation, reaching a maximum after 4 h (data not shown for 4 h). This seruminduced cyclin D1 up-regulation was inhibited by 60% in LY294002 treated cells ( Figure 7B ). These results indicate that the PI3K/Akt pathway may have stimulated the cell cycle via Akt inactivation of GSK3b, permitting increased stability and higher levels of cyclin D1.
Anti-sense ErbB3 oligonucleotide reduces proliferation of human lung adenocarcinoma cell lines An anti-sense (AS) oligonucleotide specific for human ErbB3 was used to evaluate the effect of inhibiting ErbB3 in these human lung cancer cell lines. Scrambled and sense oligonucleotides were used as controls. Treatment of H441 and H1373 lung cancer cells with 1 mM ErbB3 AS oligonucleotide resulted in significant, 60±75% reduction in ErbB3 protein levels whereas control oligonucleotides had no significant effect (Figures 8A and 9) . The expressions of ErbB2, p85 and Akt were not markedly altered, indicating that the effects of AS ErbB3 were sequence-specific and did not involve general toxicity ( Figure 8A ; ErbB2 data not shown). Co-immunoprecipitation experiments with the ErbB3 AS treated cell lysates indicated that the down-regulation of ErbB3 protein correlated with reduced p85 pull down ( Figure 8B) .
In order to assess growth-suppressive effects of the AS directly, the MTT assay for viable cells was used. The growth of cell lines H441 and H1373, which highly express ErbB3, was inhibited by ErbB3 AS treatment ( Figure 9A ). Compared with Lipofectin transfected or sense oligonucleotide treated cells, a highly significant reduction in the average number of cells was observed after treatment with 1 mM AS oligonucleotide, in both H441 and H1373 cells ( Figure 9A ). The decreases in average amount of ErbB3 protein are shown in Figure 9B . Both average cell numbers and ErbB3 protein levels were slightly, non-significantly lower in the scrambled antisense control compared with the sense control; this could be due to non-specific toxicity and/or retention of some affinity of the scrambled-antisense oligonucleotide for the mRNA. All of the data were combined for linear regression analysis ( Figure 9C ). This illustrated strikingly the clear significant association between the ErbB3 protein level and the cell numbers in H441 and H1373 (P 0.011).
To confirm the specificity of the effects of ErbB3 AS oligonucleotide treatment on proliferation, we examined adenocarcinoma lines H23 and H1792, which express little or no ErbB3 protein ( Figure 10A) . RT±PCR experiments have indicated that the ErbB3 gene is present in H23 and H1792 cells, but full-length ErbB3 transcripts are lacking (data not shown). Proliferation of these cells was not affected by any of the oligonucleotide treatments ( Figure 10B ). These results strongly confirm that ErbB3 plays a major role in the proliferation of lung carcinoma cells expressing high levels of this protein.
Discussion
The present results provide possibly the first mechanistic evidence for a significant role for ErbB3 in human lung adenocarcinomas, and confirmation of the importance of the PI3K/ Akt pathway in this type of cancer. We have found that ErbB3 was highly expressed in the majority of lung adenocarcinoma cell lines tested, in contrast to its absence from a nontransformed cell line derived from human lung peripheral epithelium. The results may indict ErbB3 over-expression in the genesis and maintenance of many lung adenocarcinomas. ErbB2 amplification is not common in lung cancer (51) . It may be that over-expression of ErbB3 is the critical event leading to up-regulation of the ErbB pathway in many cases of this type of cancer.
The H23 and H1792 cell lines are examples of the minority of adenocarcinoma cell lines, which express very low ErbB3; ErbB2 was reported to be not expressed in H23 cells and ErbB2 anti-sense was without effect (52) . We found that ErbB3 antisense did not inhibit H23 or H1792 growth, an important control confirming the specificity of the effect. Mitogenic advantage during neoplastic transformation evidently is provided by an alternate pathway in these cells. For future studies, these cell lines can be used as negative controls for study of the specificity of therapies targeting ErbB3.
The constitutive ErbB2 and ErbB3 phosphorylation and ErbB2/ErbB3/p85 complexes demonstrated here in the lung adenocarcinoma cells are of particular interest. The ErbB2/ ErbB3 heterodimer is the most potent ErbB signaling complex in terms of in vitro growth and transformation (8, 38) , and can enhance drug resistance (53) . This high potency may be related to the C-terminal sequences of ErbB3 which contain binding motifs for several downstream novel signaling molecule 
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candidates (8) , and also to the low rate of internalization and characteristic recycling pathway of ErbB2-containing complexes, which prolong signal (54, 55) . ErbB3 contains at least 8 SH2 binding tyr-x-x-met motifs that, when tyrosine phosphorylated, form the high affinity binding site for the regulatory domain p85 of PI3K. Co-expression of ErbB3 with activated ErbB2 greatly augmented the transforming capability of ErbB2 in genetically engineered Rat 1 fibroblast cell lines (56) . In the context of lung, HRG was shown to be a mitogen in human fetal lung epithelial cells that express both ErbB2 and ErbB3 (12) and also in rat neonatal distal lung airway epithelial cells (57) . A 4-fold increase in ErbB2 and ErbB3 phosphorylation was noted when freshly isolated fetal human lung in serum free media was stimulated with Hrg-1 (12) . Constitutive ErbB2/ErbB3 heterodimer has been reported in HRG-expressing, non-tumorigenic, TGFa-negative human bronchial epithelial cells E6TA, and in TGFa/ErbB2 overexpressing tumorigenic E6T cells (58) . NRG-1(HRGa) induced cell proliferation in H441 cells and in H520 cells (a squamous lung carcinoma cell line) through activation of Janus kinase (JAK) and the STAT pathway (59). ErbB2-specific antibody, 2C4 treatment, which inhibits ErbB2 heterodimerization, blocked NRG1 induced JAK phosphorylation, further indicating the importance of ErbB3 and ErbB2 heterodimer in HRG-induced proliferation of these cells.
Strong in vivo evidence for the importance of ErbB3 and cooperative ErbB3 and ErbB2 signaling in lung tumors was provided by a new transgenic ErbB3 mouse lung cancer model. Lung tumors developed by these transgenic mice, the majority of which were adenocarcinomas, had not only elevated transgenic human ErbB3 expression but also high levels of endogenous ErbB2. Double transgenic rat ErbB2/human ErbB3 mice developed lung tumors with shorter latency (37) . Thus, both cell culture and animal model studies are fully consistent with our findings pointing to a central role for ErbB3 in driving proliferation in lung cancer cells.
Our data indicate that PI3K, activated by its regulatory subunit p85, and Akt transmit the cell proliferation signal from the ErbB2/ErbB3 complex. These results support studies of primary human lung cancers indicating the importance of PI3K and Akt. Over-expression of PI3K p110 mRNA by northern blotting and up-regulation of p85 and p110 protein detected by immunohistochemistry correlated with poor differentiation in NSCLC lung tumors; p85 was up-regulated in 77% of primary lung carcinomas (60) . Akt is itself a protooncogene that can transform lung epithelial cells (61) .
Fetal calf serum potently activated the PI3K pathway in SCLC cells and was the most potent growth factor for SCLC 
cells compared with stem cell factor or insulin-like growth factor (50) . The prolonged activation of Akt by serum (up to 6 h) reported for SCLC cell lines have been very similar to that reported here for lung adenocarcinoma cells. Our results confirm the importance of PI3K/Akt pathway in the proliferation of transformed lung epithelial cells.
Published results with cultured lung cells of various types are consistent. Hepatocyte growth factor induced proliferation in mink lung epithelial cells through the PI3K pathway (49) . Serum, stem cell factor and insulin like growth factor 1 activated the PI3K pathway and promoted proliferation in primary bronchial epithelial cells, MRC-5 pulmonary fibroblast and SCLC cell lines (50) . LY 294002 inhibited the proliferation induced by these growth factors and by serum in a dosedependent manner (50) . Constitutively high PI3K levels mediated anchorage independent proliferation through Akt and a P70S6 kinase-dependent pathway in small cell lung cancer cell lines (48) . Inhibition of the PI3K pathway blocked SCLC growth in liquid cultures and colony formation in semisolid medium (62) . An inducible constitutively active Akt was utilized to distinguish the proliferative from anti-proliferative effects of the PI3K/Akt pathway in SCLC cells and indicated that a threshold level of PI3K/Akt pathway activation is essential for the proliferation of SCLC cells (50) . Expression of Akt1 antisense oligonucleotide inhibited the proliferation of a lung cancer cell line, H460, and blocked its ability to grow in soft agar (63) . In addition to cell proliferation, the PI3K/Akt pathway also contributed to cell survival and therapeutic resistance in the SCLC cells.
Constitutive Akt activity was found in 16 of 17 of NSCLC cell lines and was associated with cell survival and therapeutic resistance (64) . Our results suggest that complex of p85 with ErbB3 may contribute to these effects. Dominant-negative Akt was utilized to confirm the specificity of the inhibitory effect of LY294002 (50, 64) . Apoptosis resulting from Akt inhibition was observed to varying degrees in different cell lines. Treatment of LY294002 did not induce apoptosis in four lung adenocarcinoma cell lines even though it efficiently blocked the Akt activation (65) . We observed no marked increase in apoptosis in adenocarcinoma cells after treatment with LY294002, consistent with the known lower frequency of apoptosis in this cancer type (66) .
Constitutive and growth factor-dependent PI3K recruitment by tyrosine phosphorylated ErbB3 has also been observed in other types of cancer and in fact was first evidenced in breast cancer cells (38, 67, 68) . Since then, the cancer-related interactions of ErbB family members and agonists with PI3K-controlled pathways have been extensively studied in mammary cells, and the results have been very similar to those reported here for lung carcinoma cells. A complex of ErbB2, ErbB3 and p85 was reported in a breast carcinoma cell line (39) . Constitutive ErbB3/p85 complexes either due to ligand independent over-expression of ErbB2 or HRG/ErbB3 autocrine loop have been reported in a number of ErbB3 expressing breast cancer cells (38, 39, 67, 68) . Intracellular retention of ErbB2 (69) or transfection with dominant-negative ErbB3 (42) led to dramatic decrease in ErbB3 phosphorylation, its association with PI3K, and proliferation in breast cancer cells. Treatment with Her2 blocking antibody, herceptin, blocked the constitutive phosphorylation of ErbB3, disrupted the ErbB3/p85 association, and inhibited cell proliferation in BT-474 cells (70) . An anti-ErbB3 receptor antibody inhibited growth factor independent growth and also blocked the HRG1b induced proliferation in ovarian tumor cells (41) .
Our results indicate that cyclin D1 could be an important nuclear target of the ErbB3 activated PI3K pathway in lung adenocarcinoma. Elevated cyclin D1 expression was observed in human lung carcinomas (71) and associated with poor prognosis in some studies (72, 73) . Cyclin D levels correlated with growth in mouse lung cancer lines (74) . Stable introduction of anti-sense cyclin D1 into H441 and A549, another adenocarcinoma cell line which also expresses ErbB3, resulted in marked reduction in their proliferation rate (75) . Although cyclin D1 levels are regulated in a variety of ways in cells, altered protein stability has been repeatedly demonstrated to be a critical event in lung epithelial and cancer cells (76±78). Our observation of an increase in the phosphorylation-associated inactivation of GSK3b, which would lead to increased cyclin D1 stability, is consistent with such a mechanism. Doxycyclinregulated expression of constitutively active Akt induced phosphorylation of GSK3b and stimulated growth in SCLC cells in the absence of growth factors (50) .
In summary, these findings implicate ErbB3 in lung adenocarcinoma, via an activatable complex involving PI3K and leading, downstream, to activation of Akt, inactivation of GSK3b, increase in cyclin D1, and cell cycle progression. Thus, cancer cells that over-express ErbB3 are dependent on an ErbB3-related pathway for proliferation. This discovery could have potential for lung adenocarcinoma prevention, intervention and therapy.
